| 0 | 💬 0 |
First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
(nejm.org)
|
New England Journal of Medicine 2026-04-30 | #clinical trial #nsclc #tyrosine kinase inhibitor #targeted therapy #her2 |